Ohr Pharmaceutical, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2009-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://ohrpharmaceutical.com
Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD
Phase 3
- Conditions
- Age-related Macular Degeneration
- Interventions
- Drug: Placebo Ophthalmic solution
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2017-04-27
- Lead Sponsor
- Ohr Pharmaceutical Inc.
- Target Recruit Count
- 230
- Registration Number
- NCT02727881
- Locations
- 🇺🇸
Investigational Site, Madison, Wisconsin, United States
Study of Squalamine Lactate for the Treatment of Macular Edema Related to Retinal Vein Occlusion
Phase 1
Completed
- Conditions
- Retinal Vein OcclusionMacular Edema
- Interventions
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2015-11-25
- Lead Sponsor
- Ohr Pharmaceutical Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02614937
Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration
Phase 2
Withdrawn
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Drug: Placebo Ophthalmic Solution
- First Posted Date
- 2015-07-30
- Last Posted Date
- 2017-04-27
- Lead Sponsor
- Ohr Pharmaceutical Inc.
- Registration Number
- NCT02511613
- Locations
- 🇺🇸
Investigational Site, Houston, Texas, United States
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase 2
Completed
- Conditions
- Neovascular Age Related Macular Degeneration
- Interventions
- Drug: Vehicle control
- First Posted Date
- 2012-09-05
- Last Posted Date
- 2015-06-12
- Lead Sponsor
- Ohr Pharmaceutical Inc.
- Target Recruit Count
- 142
- Registration Number
- NCT01678963
- Locations
- 🇺🇸
Cumberland Valley Retina Consultants, Hagerstown, Maryland, United States
🇺🇸Colorado Retina, Golden, Colorado, United States
🇺🇸Retina Associates of Cleveland, Cleveland, Ohio, United States
Open Label Study With OHR/AVR118 in Advanced Cancer Patients With Anorexia-Cachexia
Phase 2
- Conditions
- AnorexiaCancer Cachexia
- Interventions
- Drug: OHR/AVR118
- First Posted Date
- 2010-09-21
- Last Posted Date
- 2012-11-27
- Lead Sponsor
- Ohr Pharmaceutical Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT01206335
- Locations
- 🇨🇦
Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
© Copyright 2025. All Rights Reserved by MedPath